Frontlight ResearchEarly access
Taking people in United StatesPhase 3
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
Key facts
- Who runs it
- Crinetics Pharmaceuticals Inc.
- Where
- Ann Arbor, Atlanta, Aurora, Baltimore, Charlottesville, Chicago, Dallas, Gainesville, Los Angeles, Milwaukee, Minneapolis, New Brunswick, Philadelphia, Pittsburgh, and Rochester, United StatesSee the 15 sitesAlso in 14 other countries, 63 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 150 people, planned
- Started
- 11 Dec 2025
- Expected to end
- May 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Atumelnant
- Placebo
- Record updated
- 10 November 2026
Who can take part
- Age
- 18 years to 74 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Male or female, between ≥18 to <75 years of age at the time of signing the ICF
- Willing and able to understand and adhere to the study procedures as specified in the protocol and comply with the study treatment
- Have classic CAH due to 21-OHD confirmed by the Investigator
- Participants with Visit 2 levels of morning serum A4 as follows:; A4 >ULN and treated with <11 mg/m2/day (physiologic) GC doses; OR normal A4 (>0.5xULN to ≤1xULN) and treated with ≥14 mg/m2/day GC doses; OR A4 >ULN and treated with ≥11 mg/m2/day GC doses
- On a stable (defined as no dose change of >5 mg/day hydrocortisone equivalent within 2 months prior to Screening) regimen of GC replacement (e.g., hydrocortisone, prednisolone, prednisone, methylprednisolone, meprednisone, dexamethasone, cortisone acetate) at the time of informed consent
- If treated with mineralocorticoids (fludrocortisone), the dose should be stable for at least 1 month prior to Screening without orthostatic hypotension, and with serum sodium and potassium in the normal range
- If on estrogen therapy (any route), the dose must be stable for at least 3 months prior to Screening
Who cannot take part
- Concomitant mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study, and/or evidence of poor compliance with medical instructions
- Use of atumelnant prior to screening
- History of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic GC therapy
- History of cancer excluding cured/treated dermal squamous or basal cell carcinoma or cervical carcinoma in situ
- Known history of, or concern for, risk of hypersensitivity reaction to atumelnant or any of its excipients
- Participants with an increased risk of developing adrenal insufficiency as judged by the Investigator
- Clinically significant medical condition or abnormal laboratory tests, as judged by the Investigator, other than CAH
- Diagnosis of any form of CAH other than classic 21-OHD
- Women who are pregnant or lactating or, if of childbearing potential, who are unwilling to use highly effective contraception as described in this study. Male participants who are unwilling to use highly effective contraception as described in this study
- Severe erythrocytosis as judged by the Investigator
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 74 years old?
Where in United States
Also in 14 other countries, 63 sites
- Ann Arbor, MichiganHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Atlanta, GeorgiaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Aurora, ColoradoHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Baltimore, MarylandHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Charlottesville, VirginiaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Chicago, IllinoisHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Dallas, TexasHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Gainesville, FloridaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Los Angeles, CaliforniaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Milwaukee, WisconsinHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Minneapolis, MinnesotaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- New Brunswick, New JerseyHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Philadelphia, PennsylvaniaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Pittsburgh, PennsylvaniaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
- Rochester, MinnesotaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.
The 2 groups in the trial
- TreatmentTreatment being tested
Atumelnant tablet, administered orally, once daily for 32 weeks.
Treatment: Atumelnant
- PlaceboPlacebo, for comparison
Matching placebo, administered orally, once daily for 32 weeks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)
- Criteria questions
- Built from NCT07144163, who can take part
- Record updated
- 10 November 2026